Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB 722 CL PK and Tolerability in Healthy Subjects
NCT02227030Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2000
- Primary completion
- Sep 2000
01
Overview
Phase 1, randomised, double-blind trial of eniporide in ischemia-reperfusion injury (IRI) (4 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at 96 hours, Maximum measured concentration at 96 hours and 3 more. Started Apr 2000; status: completed.
02
Drugs
eniporide
03
Conditions
ischemia-reperfusion injury (IRI)
Beyond the preview
Go deeper on NCT02227030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227030.